’·è‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È •ªŽq–ò—Šw•ª–ì
publication
HOME
‹³Žöˆ¥ŽA
ƒƒ“ƒo[Ð‰î
Œ¤‹†ŠT—vEŒ¤‹†‚Ö‚Ì—U‚¢
Œ¤‹†‹ÆÑ
‹³ˆçŠˆ“®
Šw‰ïEŒ¤‹†‰ïEƒƒfƒBƒAŒfÚ
sŽ–
•åW
ƒAƒNƒZƒX
 
’·è‘åŠwd“_‰Û‘èu’ɂݍŽ•ž‚̍‘Û“IŒ¤‹†‹³ˆç‹’“_‚ÌŒ`¬v
 
 
 
Œ¤‹†‹ÆÑ
ƒz[ƒ€>Œ¤‹†‹ÆÑ>‰¢•¶‘à

‰¢•¶‘à
  1.  Ueda H Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain.PAIN. 158(4):55-65,2017.4
  2. Ueda H,Uchida H. Epigenetic Modification in Neuropathic Pain.Curr Pharm Des. 21(7)849-67.2015 @@@@@@@@@@@
  3. Pavone F, Ueda HFBridging the Gap Is BoNT/B useful for pain treatment?.@PAIN@155(4)674-684,2014
  4. Ueda H, Matsunaga H, Olaposi Omotuyi I., Nagai J: Lysophosphatidic acid: Chemical signature of neuropathic pain. Biochim Biophys Acta. 1831(1): 61-73, 2012
  5. Ueda H, Matsunaga H, Halder S K: Prothymosin alpha plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms. Ann N Y Acad Sci. 1269(1)34-43
  6. Hiroshi Ueda: Lysophosphatidic acid as the initiator of neuropathic pain. Biol Pharm Bull. 34(8):1154-1158, 2011
  7. Hiroshi Ueda and Mutsumi Ueda: Lysophosphatidic acid as initiator of neuropathic pain - biosynthesis and demyelination. Clin Lipidol. 6(2):147-158, 2011
  8. Ueda H, Matsunaga H, Uchida H, Ueda M: Prothymosin Alpha as Robustness Molecule against Ischemic Stress to Brain and Retina. Ann N Y Acad Sci 1194: 20-26, 2010
  9. Ueda H: Prothymosin alpha@and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. Pharmacology & Therapeutics, 2009 Sep;123(3):323-33. Epub 2009 Jun 3.
  10. Ueda H, Ueda M: Mechanisms underlying morphine analgesic tolerance and dependence ? plasticity in opioid receptor signaling, trafficking and neural networks. Frontiers in Bioscience, 2009 Jun 1;14:5260-72.
  11. Ueda H: Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination. Mol. Pain Apr 1;4:11, 2008
  12. Ueda H:Prothymosin alpha plays a key role in cell death mode-switch, a new concept for neuroprotective mechanisms in stroke Naunyn-Schmiedebergfs Archives of Pharmacology. 377(4-6):315-23, 2008
  13. Ueda H; Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms.;Pharmacol Ther. Jan;109(1-2):57-77, 2006
  14. Ueda H.: Locus-Specific Involvement of Anti-Opioid Systems in Morphine Tolerance and Dependence. Annals of the New York Academy of Sciences  Oct;1025:376-82. 2004
  15. Ueda H.: Cell death mode switch from necrosis to apoptosis in brain; Current Topics Mitochondria and Neuroprotection; Bio Pharm. Bull. 27(7); 950-955.
  16. Ueda H.: Foreword; Current Topics Mitochondria and Neuroprotection; Bio Pharm. Bull. 27(7); 949.
  17. Ueda H. and Rashid MH: Morecular mechanisms of neuropathic pain; in Drug News Perspect; 2003 Nov; 16(9); 605-613.
  18. Usdin T.B. Dobolyi A. Ueda H. and Palkovits M.; Emerging functions for tuberoinfundibular peptide of 39 residues; In: Trends Endocrin Met; 2003 Jan;14(1), 14-19.
  19. Yamamoto Y. Ono H. Ueda H. Shimamura M. Nishimura K. and Hazato T.; Spinorphin as an Endogenous Inhibitor of Enkephalin-degrading Enzymes: Roles in Pain and Inflammation; Curr Protein Pept Sci.; 2002 Dec; 3(6);587-599.
  20. Yoshida A. and Ueda H.; Neurobiology of lysophosphatidic acid receptor; In: Jpn J Pharmacol.; 2001; 87, 104-109.
  21. Ueda H. In Vivo Molecular Signal Transduction of Peripheral Mechanisms of Pain; In: Jpn. J. Pharmacol.; 1999; 79(3), 263-268.
  22. Misu Y. Goshima Y. Ueda H. and Okamura H.; Neurobiology of L-DOPA ergic system; In: Prog. Neurobiol.; 1996; 49(5): 415-454.
  23. Ueda H. Nozaki M. and Satoh M.; Multiple opioid receptors and GTP-binding proteins; In: Comp. Biochem. and Physiol.; 1991; C 98(1): 157-169.
 
 
’·è‘åŠw
 
Copyright